SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 8.0% Stake in Ascendis Pharma AS
Beneficial Ownership Report
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% of Ascendis Pharma AS's common stock as of March 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 4,646,943 shares of Ascendis Pharma AS common stock.
- This ownership represents 8.0% of the total outstanding common stock of Ascendis Pharma AS.
- FMR LLC holds sole voting power over 4,646,765 shares and sole dispositive power over 4,646,943 shares.
- Abigail P. Johnson, as Chairman and CEO of FMR LLC and a predominant owner of its voting shares, is deemed to have sole dispositive power over the same 4,646,943 shares.
- The filing is an Amendment No. 11 to a Schedule 13G, indicating an update to a previously reported significant stake.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership filing (Schedule 13G Amendment), providing factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- The disclosure of a significant 8.0% stake by a major institutional investor like FMR LLC can signal confidence in Ascendis Pharma AS.
- The filing explicitly states that the shares are held in the ordinary course of business, indicating a passive investment rather than an activist intent.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Regulatory Authorities: Fulfills SEC disclosure requirements for significant ownership stakes.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (reporting date for ownership). |
| 05/09/2025 | Date of signing and agreement for joint filing of the Schedule 13G. |
Keywords
Ascendis Pharma AS, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, ownership disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.